Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
Authors:
- Kristian ReichKRKristian Reich
- Diamant ThaçiDTDiamant Thaçi
- Georg StinglGSGeorg Stingl
- Jens Strodl AndersenJAJens Strodl Andersen
- Line Conradsen HiortLHLine Conradsen Hiort
- Michala Oron LexnerMLMichala Oron Lexner
- David WinklerDWDavid Winkler
- Carle PaulCPCarle Paul
Open Access
- 28 March 2022
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 102, adv00683
Abstract
Brodalumab is approved for treatment of moderate-to-severe plaque psoriasis. Here, we assess the safety profile of brodalumab using pooled safety data from 5 phase II/III trials of brodalumab 140 mg or 210 mg. In total, 4,464 patients received brodalumab, representing 8,891.6 patient-years of exposure. During the placebo-controlled 12-week induction period, rates of serious adverse events per 100 patient-years were 10.8 and 9.6 (brodalumab 140 mg and 210 mg, respectively) vs 4.3 and 6.5 (ustekinumab and placebo, respectively); infections were the most frequent serious adverse event. Rates of serious adverse events during the comparator-controlled 52-week period were 14.4, 10.2 and 8.3 per 100 patient-years for brodalumab 210 mg, brodalumab 140 mg, and ustekinumab, respectively. Brodalumab was not associated with increased risks of malignancy, major adverse cardiac events, suicidal ideation and behaviour, or fatal events. Overall, brodalumab demonstrated an acceptable safety profile in short- and long-term treatment.Keywords
This publication has 27 references indexed in Scilit:
- Psoriasis and comorbid diseasesJournal of the American Academy of Dermatology, 2017
- Brodalumab: The first anti-IL-17 receptor agent for psoriasisDrugs of Today, 2017
- Co-morbidity in psoriasis: mechanisms and implications for treatmentExpert Review of Clinical Immunology, 2016
- A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasisBritish Journal of Dermatology, 2016
- Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort studyBritish Journal of Dermatology, 2016
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in PsoriasisNew England Journal of Medicine, 2015
- Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatmentJournal of the American Academy of Dermatology, 2014
- Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti–IL-17 Receptor Monoclonal AntibodyThe Journal of Immunology, 2014
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for PsoriasisNew England Journal of Medicine, 2012
- Intention-to-treat concept: A reviewPerspectives in Clinical Research, 2011